-
GE Healthcare and NVIDIA Expand Partnership to Advance Autonomous X-ray and Ultrasound Technologies
•
US medical device and life sciences giant GE Healthcare Technologies Inc. (NASDAQ: GEHC) announced an expanded partnership with US-based chip giant NVIDIA (NASDAQ: NVDA) focused on the innovative application of autonomous X-ray technologies and ultrasound. This collaboration aims to transform medical imaging through artificial intelligence. Partnership DetailsThe expanded partnership will…
-
Illumina Partners with NVIDIA to Advance Multiomic Data Analysis
•
US-based genomics giant Illumina (NASDAQ: ILMN) has announced a strategic partnership with chip manufacturer NVIDIA (NASDAQ: NVDA) to advance technology platforms for the analysis and interpretation of multiomic data. This collaboration aims to accelerate progress in clinical research, genomics AI development, and drug discovery, leveraging the strengths of both companies…
-
NVIDIA Expands Healthcare Reach with Amgen’s deCode Partnership at JP Morgan Conference
•
At the recent JP Morgan Healthcare Conference, US chip giant NVIDIA (NASDAQ: NVDA) announced a new collaboration with Amgen (NASDAQ: AMGN)’s subsidiary, deCode. This partnership will see deCode leverage NVIDIA’s advanced supercomputers and the BioNeMo generative artificial intelligence (AI) platform to bolster the development of its genomic foundational models. BioNeMo,…
-
Genentech and NVIDIA Collaborate to Advance Drug Discovery with AI
•
Genentech, a subsidiary of Swiss pharmaceutical giant Roche (SWX: ROG), has entered into a collaboration agreement with semiconductor manufacturer NVIDIA (NASDAQ: NVDA) to expedite drug discovery and development. This partnership aims to harness the power of artificial intelligence (AI) by integrating Genentech’s biological and molecular datasets with NVIDIA’s advanced supercomputing…
-
Bayer Shifts Focus of Recursion Pharmaceuticals Collaboration to Precision Oncology
•
Germany-headquartered Bayer (ETR: BAYN) has announced a significant modification to its 2020 drug discovery collaboration with US biotechnology firm Recursion Pharmaceuticals (NASDAQ: RXRX). The partnership, which was initially focused on fibrosis, will now shift its attention to precision oncology. This strategic move will see the initiation of up to seven…
